Abstract Number: 557 • ACR/ARP Annual Meeting 2019
Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey
Background/Purpose: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare…Abstract Number: 1400 • ACR/ARP Annual Meeting 2019
Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib (Xeljanz) is an approved treatment for Rheumatoid Arthritis (RA) but data on its use in “real life” are limited. We sought to analyze…Abstract Number: 2162 • ACR/ARP Annual Meeting 2019
Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)
Background/Purpose: Total joint replacement (TJR) is performed when severe large joint destruction causes functional disability in patients with rheumatoid arthritis (RA). Biologics were approved in…Abstract Number: 504 • ACR/ARP Annual Meeting 2019
A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis
Background/Purpose: RA patients who have failed biologic DMARDs represent an unmet medical need. We explored the impact of baseline demographics and clinical characteristics on filgotinib…Abstract Number: 614 • ACR/ARP Annual Meeting 2019
Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data
Background/Purpose: Tapering of tumor necrosis factor (TNF) inhibitors may be considered in patients with ankylosing spondylitis (AS) with low disease activity. However, there is still…Abstract Number: 1404 • ACR/ARP Annual Meeting 2019
Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea
Background/Purpose: Limited data are available on whether patients with rheumatoid arthritis (RA) are treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs) according to the current recommendations…Abstract Number: 2361 • ACR/ARP Annual Meeting 2019
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…Abstract Number: 507 • ACR/ARP Annual Meeting 2019
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…Abstract Number: 757 • ACR/ARP Annual Meeting 2019
Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis
Background/Purpose: Takayasu arteritis (TAK) occurs at a young age and has a long-term clinical course. Progression of arterial stenosis or dilatation leads to organ dysfunction.…Abstract Number: 1406 • ACR/ARP Annual Meeting 2019
Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial
Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…Abstract Number: 2373 • ACR/ARP Annual Meeting 2019
Two Decades of Changes in RA Treatment and Disease Outcomes from the United States
Background/Purpose: RA causes significant morbidity and mortality. Over the last two decades, several new medications and strategies for treating RA earlier and more aggressively have…Abstract Number: 508 • ACR/ARP Annual Meeting 2019
Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, demonstrated efficacy and an acceptable safety profile in a Phase 2b study (RAJ1 study, NCT01649999) and…Abstract Number: 766 • ACR/ARP Annual Meeting 2019
Predictors of Long-term Therapy with Glucocorticoid in Polymyalgia Rheumatica
Background/Purpose: Clinical symptoms of polymyalgia rheumatica (PMR) are improved by low-dose glucocorticoids (GC), but relapses and long-term GC therapy are common. 2015 EULAR/ACR recommendations suggest…Abstract Number: 1422 • ACR/ARP Annual Meeting 2019
Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA
Background/Purpose: T-cell profiles are heterogeneous between individuals and consist of naïve T cells, memory T cells (including effector memory T cells [TEM] and central memory…Abstract Number: 2377 • ACR/ARP Annual Meeting 2019
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
